Intravenous Ascorbic Acid (IVAA) for COVID-19: supportive treatment in hospitalized COVID-19 patients: based on use in China and US settings
|dc.contributor.author||Anderson, Paul S.|
|dc.description.abstract||Intravenous ascorbic acid (IVAA) is a well-known intervention in medicine, which currently is rarely used in US hospitals. Due to the unusual and extreme clinical demands of hospitalized COVID-19 patients, IVAA has been implemented in Chinese hospitals, and data published by the “Expert Group on Clinical Treatment of New Corona Virus Disease in Shanghai” (direct translation) details the use of IVAA as safe and effective adjunctive care of hospitalized COVID-19 patients. In the IVAA treated group, there was no mortality, no reported side effects, and shorter hospital stays universally. In addition, the Shanghai Expert Group recommends IVAA use in extremely critical settings within COVID-19 patients. IVAA, as an intervention, is relatively inexpensive and simple for both pharmacy and nursing staff use. The primary author has also used IVAA in the US under a NIH funded human trial and has extensive subject matter knowledge and expertise.||en_US|
|dc.title||Intravenous Ascorbic Acid (IVAA) for COVID-19: supportive treatment in hospitalized COVID-19 patients: based on use in China and US settings||en_US|
|eihealth.category||Candidate therapeutics RD||en_US|
|eihealth.maincategory||Save Lives / Salvar Vidas||en_US|
Files in this item
There are no files associated with this item.